MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/hae.70319

Медицинская библиотека · Haemophilia : the official journal of the World Federation of Hemophilia · 2026

Real-World Outcomes of Prophylaxis With rIX-FP in Germany: A Prospective, Non-Interventional Study in Haemophilia B.

Oldenburg Johannes, Wenning Swee, Holzhauer Susanne, Miesbach Wolfgang, Klamroth Robert, Linhoff Thomas, Sommerer Patrick, Pfrepper Christian, Olivieri Martin, all study investigators

СтатьяПеревод пока не подготовлен

Аннотация

INTRODUCTION

Efficacy and safety of albutrepenonacog alfa (rIX-FP) in people with haemophilia B (PwHB) has been previously demonstrated in clinical trials. However, real-world data insights are required.

AIM: To describe real-world effectiveness and tolerability of rIX-FP in PwHB in Germany.

METHODS

Prospective, non-interventional study conducted across 19 sites in Germany. Patients of any age treated with rIX-FP were enrolled between March 2018 and February 2024. Patients were monitored every 3-12 months and followed-up for 3 years or until ≥100 exposure days.

RESULTS

To our knowledge, this is the largest study of factor replacement therapy in PwHB in Germany to date. Of the patients who completed the study (63/73), most (80.8%) had moderate or severe haemophilia B. The mean (standard deviation) duration of observation was 30.5 (8.32) months. For any prophylaxis regimen, the median (range) annualised bleeding rate (ABR) was 0.89 (0.0-9.6) and annualised spontaneous bleeding rate (AsBR) was 0.08 (0.0-5.2). The median ABR was 1.12, 0.68 and 0.13, and the median AsBR was 0.17, 0.00 and 0.06 for those treated with a 7-, 10- or 14-day regimen, respectively. Investigators rated the overall haemostatic effectiveness as 'good' or 'excellent' in 94% of cases (based on the worst assessment). Overall, 82 adverse events in 34 patients were reported, none were considered related to rIX-FP.

CONCLUSION

This multicentre, non-interventional study in Germany demonstrates that rIX-FP prophylaxis is effective and well tolerated in PwHB of all ages in routine clinical practice and reinforces the results of the clinical trials.

Для цитирования: Oldenburg Johannes, Wenning Swee, Holzhauer Susanne, Miesbach Wolfgang, Klamroth Robert, Linhoff Thomas, Sommerer Patrick, Pfrepper Christian, Olivieri Martin, all study investigators. Real-World Outcomes of Prophylaxis With rIX-FP in Germany: A Prospective, Non-Interventional Study in Haemophilia B.. Haemophilia : the official journal of the World Federation of Hemophilia. 2026. DOI: 10.1111/hae.70319.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.